American Journal of Kidney Diseases
Volume 52, Issue 6, Supplement 1 , Pages S29-S33 , December 2008

Economic Considerations in a Changing Anemia Environment

  • Laura T. Pizzi, PharmD, MPH

      Affiliations

    • Corresponding Author InformationAddress correspondence to Laura Pizzi, PharmD, MPH, Department of Health Policy, Jefferson Medical College, 1015 Walnut St, Ste 115, Philadelphia, PA

References 

  1. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernán MA. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA. 2007;297:1667–1674
  2. Wish JB. The economic realities of erythropoiesis-stimulating agent therapy in kidney disease. Kidney Int Suppl. 2006;70:S21–S25
  3. Leavitt MO. Secretary of Health and Human Services Report to Congress: A Design for a Bundled End-Stage Renal Disease Prospective Payment System, 2008. http://www.cms.hhs.gov/ESRDGeneralInformation/Downloads/ESRDReportToCongress.pdfAccessed April 24, 2008
  4. US Renal Data System. USRDS 2007 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007;
  5. FDA. Aranesp (darbepoetin alfa) for injection: Prescribing information. Silver Spring, MD: US Food and Drug Administration (USFDA); March 2008;
  6. FDA. Procrit (epoetin alfa) for injection: Prescribing information. Silver Spring, MD: US Food and Drug Administration (USFDA); March 2008;
  7. Sunder-Plassmann G, Hörl WH. Erythropoietin and iron. Clin Nephrol. 1997;47:141–157
  8. Taylor JE, Peat N, Porter C, Morgan AG. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 1996;11:1079–1083
  9. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26:41–46
  10. Sepandj F, Jindal K, West M, Hirsch D. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant. 1996;11:319–322
  11. Michael B, Trout JR, Hoel G, et al. Effectiveness of continuous low-dose intravenous ferric gluconate therapy for maintaining Hgb and decreasing epoetin requirements in hemodialysis patients. Presented at: American Society of Nephrology Annual Meeting, San Francisco, CA, November 2 2007;(abstr)
  12. Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant. 1995;10:2070–2076
  13. Kapoian T, O'Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19:372–379
  14. Coyne DW, Kapoian T, Suki W, et al. DRIVE Study Group Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18:975–984
  15. Pizzi LT, Bunz TJ, Goldfarb DS, Coyne DW, Singh AK, et al. Ferric gluconate yields cost-savings in hemodialysis patients with high ferritin and low TSAT: Results from the DRIVE studies. Presented at: American Society of Nephrology Annual Meeting, San Francisco, CA, November 2 2007;(abstr)
  16. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(suppl 3):S11–S145

 This article was published as part of a supplement sponsored by an educational grant from Watson Pharmaceuticals.

PII: S0272-6386(08)01302-4

doi: 10.1053/j.ajkd.2008.09.001

American Journal of Kidney Diseases
Volume 52, Issue 6, Supplement 1 , Pages S29-S33 , December 2008

Article Tools